Beneficiality of levosimendan for Takotsubo syndrome remains uncertain

With interest we read the article by Guo et al. about a study of levosimendan as an adjunctive treatment of 100 patients with Takotsubo syndrome (TTS) (1). The authors concluded that levosimendan “showed reliable efficacy and safety in Chinese elderly patients with TTS, supporting the idea that levosimendan has the potential to be an essential drug applied for patients with TTS” (1). We have the following comments and concerns.